UK watchdog flags competition concerns in Unilever-McCormick deal

What happened

On November 11, 2026, the UK's competition authority expressed concern that a food deal between Unilever and McCormick may weaken competition, potentially complicating Unilever's portfolio streamlining efforts. This regulatory scrutiny adds another layer of execution risk to Unilever's ongoing transformation, which already includes a complex Ice Cream demerger and an €800 million productivity programme. The master report characterizes Unilever as a high-quality, cash-generative franchise with strong brands and a conservative balance sheet, but notes the stock trades at a rich ~32x P/E and ~39% above its DCF-based intrinsic value. Management is refocusing on 30 Power Brands and higher-growth Beauty & Wellbeing and Personal Care, and the McCormick deal is part of reshaping the Foods portfolio. While the immediate financial impact of the competition concern is likely modest, it underscores the broader execution and regulatory headwinds facing the company's transformation agenda.

Implication

Investors should treat this regulatory development as a reminder that portfolio reshaping actions are subject to external approval and may face delays or modifications. The master report's 'POTENTIAL SELL' stance remains appropriate given Unilever's rich valuation and the multiple execution risks, including the Ice Cream demerger and productivity savings delivery. No immediate action is required based on this news alone, but it adds to the watch list of items that could pressure the stock if progress on the transformation stalls. Existing holders may consider trimming positions, while new capital should await a price correction or clearer evidence of successful execution. Over the medium term, sustained growth above the 3-5% target and margin expansion could alter the thesis, but for now the risk-reward is unfavorable.

Thesis delta

The competition concern does not alter the core thesis that Unilever is a quality franchise trading at a premium valuation. It marginally increases the execution risk associated with portfolio reshaping, reinforcing the existing caution. The overall judgment remains 'POTENTIAL SELL' pending evidence of successful transformation and more attractive valuation.